Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee.
Topol EJ, Armstrong P, Van de Werf F, Kleiman N, Lee K, Morris D, Simoons M, Barbash G, White H, Califf RM. Topol EJ, et al. J Am Coll Cardiol. 1992 May;19(6):1123-8. doi: 10.1016/0735-1097(92)90312-b. J Am Coll Cardiol. 1992. PMID: 1564212 Free article. Clinical Trial.
Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, Califf RM, Berger PB, Topol EJ. Holmes DR Jr, et al. Among authors: kleiman ns. J Am Coll Cardiol. 1995 Sep;26(3):668-74. doi: 10.1016/0735-1097(95)00215-p. J Am Coll Cardiol. 1995. PMID: 7642857 Free article. Clinical Trial.
Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM, Holmes DR Jr, Bates E, Pfisterer M, Vahanian A, et al. Kleiman NS, et al. Circulation. 1994 Dec;90(6):2658-65. doi: 10.1161/01.cir.90.6.2658. Circulation. 1994. PMID: 7994805 Clinical Trial.
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.
Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Kleiman NS, et al. J Am Coll Cardiol. 1993 Aug;22(2):381-9. doi: 10.1016/0735-1097(93)90041-x. J Am Coll Cardiol. 1993. PMID: 8335808 Free article. Clinical Trial.
Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL. Kereiakes DJ, et al. Among authors: kleiman ns. J Am Coll Cardiol. 1996 Mar 1;27(3):536-42. doi: 10.1016/0735-1097(95)00500-5. J Am Coll Cardiol. 1996. PMID: 8606262 Free article. Clinical Trial.
487 results